Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck stock snapshot after recent performance Merck (MRK) has drawn fresh attention after a period where the share price and ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

Merck quashed fourth-quarter expectations Tuesday, but the Dow Jones health giant issued lackluster expectations for 2026.

Merck & Co., Inc. stock reached a 52-week high, closing at $112.91. This milestone reflects a significant upward trend for the pharmaceutical giant, with its stock price appreciating by 13.07% over ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...

Merck beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $17.28 billion, up 3.7% year on year. It was a strong quarter for the company, with a solid beat of analysts’ ...